Bookmark
Forward
QuickView for methicillin (compound)
PubChem
| Name: | Methicillin |
|---|---|
| PubChem Compound ID: | 10670288 |
| Description: | One of the PENICILLINS which is resistant to PENICILLINASE but susceptible to a penicillin-binding protein. It is inactivated by gastric acid so administered by injection. |
| Molecular formula: | C23H18N4O3S |
| Molecular weight: | 430.48 g/mol |
DrugBank
Identification
| Name: | Methicillin |
|---|---|
| Name (isomeric): | DB01603 |
| Drug Type: | small molecule |
| Description: | One of the PENICILLINS which is resistant to PENICILLINASE but susceptible to a penicillin-binding protein. It is inactivated by gastric acid so administered by injection. |
| Synonyms: |
Meticilina [inn-spanish]; Methycillin; Methicillinum; Meticilline [inn-french]; (2,6-Dimethoxyphenyl)penicillin; 6-(2,6-Dimethoxybenzamido)penicillanic acid; Meticillinum [inn-latin]
|
| Brand: | Metacillin, Dimocillin |
| Category: | Anti-Bacterial Agents, Penicillins |
| CAS number: | 61-32-5 |
Pharmacology
| Indication: | Used to treat infections caused by susceptible Gram-positive bacteria, particularly beta-lactamase-producing organisms such as <i>Staphylococcus aureus</i> that would otherwise be resistant to most penicillins. |
|---|---|
| Pharmacology: |
Meticillin (INN, BAN) or methicillin (USAN) is a narrow spectrum beta-lactam antibiotic of the penicillin class. It is no longer clinically used. Its role in therapy has been largely replaced by flucloxacillin and dicloxacillin, however the term methicillin-resistant Staphylococcus aureus (MRSA) continues to be used to describe Staphyloco...
show more » |
| Mechanism of Action: |
Like other beta-lactam antibiotics, meticillin acts by inhibiting the synthesis of bacterial cell walls. It inhibits cross-linkage between the linear peptidoglycan polymer chains that make up a major component of the cell wall of Gram-positive bacteria. It does this by binding to and competitively inhibiting the transpeptidase enzyme used by bacter...
show more » |
| Absorption: | Not absorbed following oral administration. |
| Biotransformation: | Hepatic (20-40%). |
| Half Life: | 25-60 minutes |
| Affected organisms: | Enteric bacteria and other eubacteria |
Interactions
| Drug interaction: |
|
|---|
Targets
